Coherus BioSciences (CHRS) Stock Forecast & Price Target

Coherus Oncology Inc. demonstrated a positive financial performance with an annual net revenue of $267 million, showing a 4% year-over-year increase, attributed in part to a 37% rise in new accounts purchasing its PD-1 inhibitor, LOQTORZI. The company reported notable progress in the LOQTORZI launch, achieving $7.5 million in sales during the fourth quarter, which represented a 29% quarter-over-quarter growth. Additionally, with favorable clinical data from partnerships and a strategy to enhance awareness and uptake of LOQTORZI, Coherus is positioned to capitalize on market opportunities, especially in light of competitive dynamics surrounding other oncology treatments.

Coherus Oncology reported a significant decline in total revenue for 4Q24, with a 40.8% drop to $54.1 million compared to the previous year, which raises concerns about the sustainability of its financial performance. Despite a reduction in SG&A expenses by 16.6% year-over-year, the company's non-GAAP loss per share of $0.62 exceeded both management expectations and street consensus, reflecting operational challenges. The company faces multiple risks, including regulatory hurdles, intense competition from larger firms, and potential intellectual property issues, all of which could impede the successful launch and market penetration of its pipeline assets, including LOQTORZI.